Nahid Bhadelia

Dr. Bhadelia is an Associate Professor of Medicine in the Section of Infectious Diseases and the Medical Director of Special Pathogens Unit at Boston Medical Center. She specializes in infection-control issues related to emerging pathogens and highly communicable infectious diseases. She is the director of the medical response program for BU’s biosafety level 4 laboratories at the NEIDL and provides input into BU’s Research Occupational Health policies related to infectious diseases. Her research interests are related to comparative effectiveness of hospital epidemiology practices as well as the impact of emerging diseases on health systems, and  identification of safe and effective clinical interventions and infection control measures related to viral hemorrhagic fevers.

During the West African Ebola epidemic, she served as a clinician in several Ebola treatment units, working with World Health Organization and Partners in Health. She currently serves as the clinical lead for the Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) program which a joint US-Ugandan effort to create clinical research capacity to combat viral hemorrhagic fevers in Uganda at the border of Democratic Republic of Congo. She serves on national and interagency groups focused on medical countermeasures, the intersection between public health preparedness, research and clinical care for emerging pathogens. She has served as a subject matter expert to US Centers for Disease Control and Prevention, Department of Defense, Global Fund to Fight AIDS, Tuberculosis and Malaria, and World Bank.

Selected Publications

1. McLellan S, Kortepeter MG, Bhadelia N, Shenoy ES, Sauer LM, Frank MG, Cieslak TJ. Ebola in the DRC one year later – Boiling the frog? Int J Infect Dis. 2019 08; 85:212-213. PMID: 31330320.
2. Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O’Dempsey T, Paweska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z. New filovirus disease classification and nomenclature. Nat Rev Microbiol. 2019 May; 17(5):261-263. PMID: 30926957.
3. Bhadelia N, Sauer L, Cieslak TJ, Davey RT, McLellan S, Uyeki TM, Kortepeter MG. Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines. Health Secur. 2019 Jan/Feb; 17(1):46-53. PMID: 30724616.